
The latest update is out from Korsana Biosciences ( ($KRSA) ). On November 13, 2026, Korsana Biosciences held a special shareholder meeting exclusively online via live webcast. Of 45,541,358 shares
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| KRSA | Korsana Biosciences | 37.56 | 27.20 | 262.55% |
| Name | Price | % Change | |
|---|---|---|---|
| $37.56 | +262.55% |

The latest update is out from Korsana Biosciences ( ($KRSA) ). On November 13, 2026, Korsana Biosciences held a special shareholder meeting exclusively online via live webcast. Of 45,541,358 shares

Wells Fargo initiated coverage of Korsana Biosciences (KRSA) with an Overweight rating and $44 price target The company’s core technology utilizes a transferrin receptor shuttle that delivers drug to the

As previously reported, Guggenheim analyst Yatin Suneja initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $70 price target. KRSA-028 is a second-generation monoclonal antibody delivering greater than

Wedbush analyst Laura Chico initiated coverage of Korsana Biosciences (KRSA) with an Outperform rating and $44 price target The firm believes the company’s next-generation anti-amyloid-C KRSA-028 offers “about as much

Wedbush analyst Laura Chico initiated coverage of Korsana Biosciences (KRSA) with an Outperform rating and $44 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking

Guggenheim initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $70 price target KRSA-028 is a second-generation shuttled anti-Abeta monoclonal antibody built on the proprietary THETA platform, notes

Guggenheim initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $70 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

TD Cowen initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and no price target The firm believes the company has the superior brain shuttle technology for Alzheimer’s disease.

Stifel initiated coverage of Korsana Biosciences (KRSA) with a Buy rating and $43 price target Korsana is a neuroscience focused biotech company that is pioneering the advancement of multiple drug

Korsana Biosciences ( ($KRSA) ) just unveiled an update. On September 8, 2026, Korsana Biosciences completed its merger with Cyclerion Therapeutics, ending Cyclerion’s status as a shell company and rebranding
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.